arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

TANDEM DIABETES CARE INC

TNDM
$16.37 ▼ -1.13 (-6.46%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
15 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

TANDEM DIABETES CARE INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.1B
Dividend Yield —
Revenue Growth 7.9% ↘
Op. Margin -18.5% ↘
ROIC -41.1% ↘
FCF / Share $-0.44 ↘
Trailing P/E —
Price / Book 7.2x
FCF Yield —
Debt / Equity 2.00
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.01B
↑ +7.9% —
Net Income Profit after all expenses
$-204.71M
↓ -113.2% —
Operating Margin Operating profit as % of sales
-18.5%
↓ -75.0% 11th
FCF / Share Free cash flow per share
$-0.44
↓ -677.9% —
Long-Term Debt Long-term obligations
$310.04M
↑ +0.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
14
Returns
6
Financial Health ↑
16
Cash Quality ↓
27

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters